ArticlePharmacoEconomics2024
Using Cure Modelling for Cost Effectiveness in the NICE Technology Appraisal of Polatuzumab Vedotin in Combination for Untreated Diffuse Large B Cell Lymphoma: An External Assessment Group Perspective.
Keith Cooper et al.PubMed ↗Publisher ↗
No numbers read from the abstract.